Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Kate Kelley, Robin; Rimassa, Lorenza; Cheng, Ann‐Lii; O. Kaseb, Ahmed; Qin, Shukui; X. Zhu, Andrew; L. Chan, Stephen; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; В. Бредер, В.; Verset, Gontran; Gane, Edward; Borbath, Ivan; David Gomez Rangel, Jose; Ryoo, Baek‐Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Banerjee, Kamalika; Hazra, Saswati; Fawcett, Jonathan; Yau, Thomas

doi:10.1016/s1470-2045(22)00326-6

Public

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Published in The Lancet Oncology • Jul 4, 2022

Authors:

Robin Kate Kelley

Lorenza Rimassa

Ann‐Lii Cheng

Abstract

BACKGROUND: Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. METHODS: COSMIC-312 is an open-label,...

Subject

Medicine

Sorafenib

Hepatocellular carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!